Granted De Novo Authorization
Designed to Enhance the Clinical Value of Red Blood Cells
The Hemanext ONE® Red Blood Cell (RBC) Processing and Storage system limits oxygen, the fuel for oxidative damage, providing a higher quality blood product.1,2,3
Science & Innovation Forum – Pros & Cons of Big & Small Data in RBC Biology Followed by: Perspectives on A New Innovation in RBC Processing and Storage
Please note: AABB reserves the right to make updates to this program.
When: Thursday, November 30, 2023, 2:00 – 3:00 PM (ET)
Presented by Hemanext®, an AABB Premium Corporate Partner.
Latest News & Events
Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo...
Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth
LEXINGTON, Mass., September 18, 2023, – Hemanext Inc., a leading innovator in blood processing,...
LEXINGTON, Mass., July 5, 2023, – Hemanext Inc., a leading innovator in blood processing, storage,...
Partnership to include research and development at Vitalant Innovation Center LEXINGTON, Mass.,...
Current and prospective investors access to the investor Portal
COVID 19 Updates
Follow the course of COVID-19 and locate where to donate blood
View educational material and interesting presentations
Learn about the journey of red blood cells after donation including degradation that occurs during storage and discover the potential of hypoxic storage to alleviate this problem.
Numerous studies pertaining to clinical implications of storage lesion suggest a linkage to hyper-coagulability, inflammation, impaired perfusion, immuno-modulation, organ dysfunction13, and mortality14.
Learn more about Hemanext and take a closer look at our publications, studies, and posters focused on blood quality and red blood cell characterization.